Robert Duggan
Source of wealth: Pharmaceuticals
...
...
Modules
Biography
In 2020, Robert Duggan invested $63 million in Nasdaq-listed Summit Therapeutics and became its Co-CEO, leading the biotech in developing targeted oncology therapies for difficult diagnoses.
Pharmacyclics' cancer drug Imbruvica made Duggan a billionaire in 2013 and paved the way for the company's $21 billion sale to AbbVie in 2015.
Duggan, whose son died from brain cancer, became passionate about Pharmacyclic's cancer fighting drugs and first invested in 2004.
His enthusiasm for investing began four decades earlier in a corporate finance class he took at the University of California at Santa Barbara.
In 2020, Duggan bought $63 million of shares in Nasdaq-listed Summit Therapeutics, a small biotech company, and became its CEO.
Duggan also sits on the board of Pulse Biosciences, of which he is the largest individual shareholder.
Financial Assets
The Great Lie of Mega-Fortunes: The Case of Robert Duggan
Billionaires are often presented under the romantic myth of the 'self-made person': a narrative designed to justify opulence as the natural reward for hard work, effort, or ingenuity. However, when confronting such extreme volumes of wealth with macroeconomic reality, the meritocracy narrative completely breaks down. No individual can legitimately generate through personal effort a fortune equivalent to millions of times the average working-class salary. Capital at the top does not grow because of exceptional talent; it expands through an implacable dynamic where accumulated money works exponentially faster than people, devouring the wealth generated by productive labor.
The immense fortune of Robert Duggan, linked to Healthcare and 'Pharmaceuticals', has not been built in a free-market vacuum, but through rent-seeking, the use of exclusive elite influence, the consolidation of monopoly positions, or inherited wealth. Far from taking real private risks, billionaire empires structurally depend on state support through direct subsidies, infrastructure use, exploitation of R&D, public contracts, and offshore tax engineering. While this wealth is equivalent to the physical weight of 79 tons of pure gold, the rest of the planet suffers from an artificial scarcity of basic resources. The fact that this wealth is enough to fully fund the public health system of DR Congo, a country with more than 105800000 million inhabitants for 5.0 years, proves that unlimited accumulation is not an entrepreneurial achievement, but the hijacking of democratic sovereignty.